FDA Approves Targeted Therapy Combo for Thyroid Cancer

On May 4, the U.S. Food and Drug Administration (FDA) approved a combination of molecularly targeted therapeutics for the treatment of a certain type of thyroid cancer. Specifically, the FDA approved the use of dabrafenib (Tafinlar) in combination with trametinib (Mekinist) for treating patients who have anaplastic thyroid cancer that cannot be removed by surgery or that has metastasized, and that tests positive for a BRAF V600E gene mutation.

Read More

Thyroid Cancer Survivor Dedicates Career to Researching Her Own Disease: The Story of Aime Franco

Aime Franco, PhD, quietly battled cancer throughout her undergraduate years at the University of Connecticut. But even as she tried to conceal her illness, a seed planted that would set her on a quest to understand more about cancer.

Read More